Form 4: Kronos Bio Director Reports Share and Option Dispositions Following Concentra Biosciences Merger

Kronos Bio, Inc. Director Elena Ridloff has filed a Form 4 detailing the disposition of common stock and the cancellation of stock options as a direct result of the company's acquisition by Concentra Biosciences, LLC.

Summary

• Kronos Bio, Inc. was acquired by Concentra Biosciences, LLC through a tender offer and subsequent merger, as per an Agreement and Plan of Merger dated May 1, 2025.
• The tender offer, completed on June 18, 2025, offered $0.57 per share in cash (the 'Cash Amount') plus one non-transferable contractual contingent value right (CVR).
• The merger became effective on June 20, 2025, resulting in Kronos Bio, Inc. becoming a wholly-owned subsidiary of Concentra Biosciences, LLC.
• Director Elena Ridloff disposed of 25,296 shares of Kronos Bio common stock at the merger price of $0.57 per share.
• All outstanding stock options held by Ms. Ridloff became fully vested and exercisable immediately prior to the merger's effective time.
• Options with an exercise price equal to or greater than the $0.57 Cash Amount were cancelled for no consideration, which applied to all of Ms. Ridloff's reported options with exercise prices ranging from $0.95 to $24.18.

Sentiment

Score: 3

Explanation: The sentiment is largely neutral as the filing reports a completed, pre-defined transaction (merger). However, it leans slightly negative for the reporting person and other option holders whose options were cancelled for no consideration due to their high exercise prices relative to the acquisition price. The low cash acquisition price of $0.57 per share also reflects a significant devaluation of the company prior to the merger.

Positives

• The merger provides a clear exit strategy and liquidity for Kronos Bio shareholders at the agreed-upon price of $0.57 per share plus a CVR.
• The CVR offers potential future value to shareholders contingent on specific future events.

Negatives

• All stock options held by Director Elena Ridloff, with exercise prices significantly above the $0.57 cash offer price, were cancelled for no consideration, resulting in a loss of potential value for those options.
• The cash offer price of $0.57 per share is very low, indicating a substantial decline in the company's valuation prior to the acquisition, which is a negative outcome for long-term shareholders.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and dependent on future events, which may or may not materialize, posing a risk to the full potential return for shareholders.
• The cancellation of out-of-the-money options for no consideration highlights the risk of significant capital loss for option holders if the company's stock price declines below their exercise price.

Future Outlook

The document primarily reports on a completed transaction and does not provide forward-looking statements or guidance regarding the future operations of Kronos Bio under Concentra Biosciences, LLC. The future value for former shareholders is tied to the contingent value rights (CVRs) which are not detailed in terms of their potential payout triggers or timelines in this filing.

Industry Context

This filing reflects a completed acquisition in the biotechnology sector, a common trend where larger entities or private equity firms acquire smaller, often clinical-stage, companies. The low acquisition price of $0.57 per share, especially when compared to the significantly higher exercise prices of the cancelled options, suggests that Kronos Bio may have faced substantial challenges or its pipeline assets did not achieve the expected valuation, leading to an acquisition at a distressed price. This scenario is not uncommon for biotech firms that do not meet clinical milestones or market expectations, leading to consolidation.

Comparison to Industry Standards

• The acquisition price of $0.57 per share for Kronos Bio is notably low, particularly when contrasted with the historical stock option exercise prices ranging up to $24.18. This indicates a significant devaluation of the company prior to the merger, which is a stark contrast to successful biotech acquisitions that often occur at a premium to recent trading prices.
• The cancellation of all out-of-the-money stock options for no consideration, as seen with Director Ridloff's holdings, is a common outcome in distressed acquisitions where the offer price falls below the option exercise prices. In more favorable industry acquisitions, options might be in-the-money or receive some compensatory value, even if out-of-the-money, to retain talent or acknowledge prior contributions.
• Without specific financial performance data for Kronos Bio leading up to the merger, or comparable acquisition multiples for similar biotech companies at a similar stage of development or with similar pipeline assets, a detailed quantitative comparison to industry benchmarks is limited. However, the terms suggest a less favorable outcome for existing equity and option holders compared to typical successful exits in the biotech industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received a cash payment of $0.57 per share and one CVR, providing a defined exit but at a significantly low valuation compared to historical stock prices and option exercise prices.
• Option Holders (including management): Those with out-of-the-money options, like the reporting person, received no consideration, indicating a substantial loss of potential value. In-the-money option holders received cash and CVRs.
• Employees: While not explicitly detailed, a change of control typically impacts employees through potential changes in compensation, benefits, roles, or organizational structure under the new parent company.
• Creditors: The company's financial obligations and liabilities are now assumed by or integrated under the new parent entity, Concentra Biosciences, LLC.

Next Steps

• Kronos Bio, Inc. will continue its operations as a wholly-owned subsidiary of Concentra Biosciences, LLC.
• Former shareholders of Kronos Bio, Inc. will receive the Offer Price ($0.57 cash plus one CVR) for each share held at the effective time of the merger.
• Holders of in-the-money options will receive cash and CVRs based on the merger terms, while out-of-the-money options were cancelled for no consideration.

Key Dates

Recommendation

Keywords

Kronos Bio, KRON, Concentra Biosciences, Merger, Acquisition, Tender Offer, SEC Form 4, Beneficial Ownership, Stock Options, Contingent Value Right, CVR, Elena Ridloff